At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Percutaneous Cryotherapy and Aerosolized GM-CSF for Pulmonary Metastases and Primary Lung Cancer
In Brief
A Phase 2 clinical trial evaluating sargramostim, flow cytometry, and 3 other interventions for Kidney Cancer and 3 related conditions. Completed, enrolled 8 participants across 1 site.
Detailed Summary
RATIONALE: Cryotherapy kills tumor cells by freezing them. Giving an injection of GM-CSF before cryotherapy and inhaling GM-CSF after cryotherapy may interfere with the growth of tumor cells and shrink the tumor. Giving cryotherapy together with GM-CSF may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cryotherapy together with GM-CSF works in treating patients with lung metastases or primary lung cancer.
Study Details
Timeline
Interventions
250 μg, inhaled, two times a day, on days 4-10 and days 36-42
Days 1 \& 32
Days 1 \& 32
CT guided biopsy on days 1 \& 32
Days 1 and 32